23 Oct 2017,
  • HSI:
    28,487.24 328.15 (1.17%)
    HSCI:
    11,558.35 200.90 (1.77%)
    HKSPLC25:
    36,549.71 384.31 (1.06%)
    HKSPGEM:
    277.93 2.87 (1.04%)
  • HSCEI:
    11,558.35 200.90 (1.77%)
    HSCCI:
    4,395.40 61.05 (1.41%)
    HSFML25:
    10,012.97 172.14 (1.75%)
    H-FIN:
    18,539.68 313.65 (1.72%)
  • Hang Seng Index
  • 28,487.24

  • 328.15 (1.17%)
HSCI 11,558.4 200.9
HKSPLC25 36,549.7 384.3
HKSPGEM 277.9 2.9
HSCEI 11,558.4 200.9
HSCCI 4,395.4 61.1
HSFML25 10,013.0 172.1
H-FIN 18,539.7 313.7
Stay Connected With EQS TodayIR

Beijing Enterprises Medical and Health Industry Group Limited (02389.HK)

Medical Supplies

INTRADAY CHART

more

FINANCIAL REPORTSmore

2017 (IR)
2016 (AR)
2016 (IR)

PRESENTATIONSmore

Beijing Enterprises Medical and Health Industry Group Limited is a company listed on the Main Board of the Hong Kong Stock Exchange (hereinafter “Beijing Enterprises Medical and Health”; HKEX stock code: 2389). It is under Beijing Enterprises Group Company Limited (hereinafter “Beijing Enterprises Group”), which is a municipal state-owned enterprise group with its establishment funded by the People’s Government of Beijing.

Being an investment and financing vehicle under Beijing Enterprises Group, Beijing Enterprises Medical and Health is principally engaged in medical care, health care and geriatric care sectors. It is committing to developing the industries of medical care, health care and geriatric care. It actively explores the development potential of the all-around healthcare sector and seeks quality partners for cooperation. It integrates social resources and capitalizes synergies so as to develop a healthcare industry with excellent preconditions and large platform. Leveraging on the high-end domestic and foreign medical resources, the group builds up a comprehensive industry chain in respect of medical and geriatric care which is people oriented, funded by financial means and supported by interactive medical technologies. One of its priorities is to continuously focus on the promotion of public–private partnership (PPP), a model highly recommended by the State, in medical sector and treats such model as its primary investment project.

Beijing Enterprises Medical and Health was selected as one of the MSCI (Morgan Stanley Capital International) China Small Cap Index on 29 May 2015.

Company Secretary
Lam Ka Tak

Principal Bankers
Bank of China
China Construction Bank
Hang Seng Bank Limited
China Citic Bank (International)

Auditors
Ernst & Young

Registered Office
Room 1110-11, 11/F., Harbour Centre,25 Harbour Road, Wan Chai, Hong Kong

Media Contacts
PRChina Limited: Ms. Jane Liu
Tel: (852) 2522 1838
Fax: (852) 2521 9955
Address: 17/F, Yat Chau Building, 262 Des Voeux Road Central, Hong Kong
Email: prchina@prchina.com.hk

Share Registrars
Union Registrars Limited
Share Registrars Tel No (852) 2849-3399

Stock code
02389

Analyst Reports
16 June 2015
CIMB Beijing’s SOE giant marching into elderly homes and hospitals

27 July 2015
轉型醫療大健康看好長期前景

MEMORANDUM AND ARTICLES OF ASSOCIATION
Shareholders Communication Policy
+ More Company Profile

Mr. Zhu Shi Xing - Executive Director and Chairman of the Board

Mr. Zhu Shi Xing was appointed as an Executive Director of the Company in September 2014. He is currently the Chairman of the Board and a member of the Nomination Committee and the Investment and Risk Management Committee of the Company. Mr. Zhu graduated from the Central University of Finance and Economics with a bachelor’s degree in finance and obtained his master degree in software engineering from Beihang University. In addition, Mr. Zhu obtained a bachelor degree in sport management from Beijing Sport University in July 1994. Mr. Zhu started his career as an assistant in the investment department of the China Xinxing Corporation (Group) Ltd. in 1994. During the period from 2004 to 2015, he joined the Beijing Holdings Limited (“BHL”), an affiliate of Beijing Properties (Holdings) Limited (“BPHL”, HKEX Stock Code: 925), and had been nominated the vice general manager of various subsidiaries of BHL involving in industries of tourism, logistics, property development and the executive vice president of BPHL. Since December 2015, Mr. Zhu is also an Executive Director of Beijing Sports and Entertainment Industry Group Limited ("BSE"), HKEX Stock Code: 1803), an associate of the Company. Mr. Zhu has extensive experience in investment, financial management and property development.

Mr. Liu Xue Heng - Executive Director and Joint Chief Executive Officer

Mr. Liu Xue Heng was appointed as an Executive Director and Joint Chief Executive Officer of the Company in September 2014 and April 2015 respectively. He is currently a member of the Investment and Risk Management Committee of the Company. Before joining the Group, he served as an executive director and the chairman of Investment and Risk Management Committee of BPHL during the period from 1 January 2011 to 23 December 2015, an executive director and the chief executive officer of Bestway International Holdings Limited (HKEX stock code: 718) during the period from 11 July 2014 to 19 January 2016, as well as an independent nonexecutive director of Guangshen Railway Co., Limited (HKEX stock code: 525) during the period from 2 June 2011 to 29 May 2014. Since January 2016, Mr. Liu is also an Executive Director of BSE. Mr. Liu obtained a Master of Business Administration from Cambridge University in the United Kingdom. He has extensive experience in equity investment, corporate finance, initial public offer, and mergers and acquisitions.

Mr. Zhang Jing Ming - Executive Director and Joint Chief Executive Officer

Mr. Zhang Jing Ming was appointed as an Executive Director and Joint Chief Executive Officer of the Company in September 2014. Mr. Zhang graduated with a master degree in international finance and trade in the University of International Business and Economics. Mr. Zhang started his property related business since 1996 being the chairman of the board and the general manager of Beijing Wanqi Holdings Ltd., a property developer in Beijing. In 2009, he was also appointed the chief executive officer of the Beijing Badachu Real Estate Group Limited. Mr. Zhang has almost twenty years’ experience in property development business.

Mr. Gu Shan Chao - Executive Director

Mr. Gu Shan Chao was appointed as an Executive Director of the Company in September 2014. He is currently the Chairman of the Investment and Risk Management Committee. Mr. Gu obtained his bachelor’s degree in electronic engineering from the Beijing Institute of Technology and a master degree in property from the Tsinghua University. Mr. Gu participated in the property industry since 1999 who had been sales director and general manager of various property developers in Beijing. Mr. Gu currently is a director of Holiday Inn Downtown Beijing Co., Ltd., a subsidiaries of BPHL.

Mr. Hu Shiang Chi - Executive Director

Mr. Hu Shiang Chi was appointed as an Executive Director of the Company in May 2015. Mr. Hu obtained his master degree in International Business and bachelor degree in electrical Engineering from National Taiwan University. Mr. Hu has extensive experience in operation management and company acquisition and is now the chairman of the board of Abico-Fs Co., Ltd (stock code in GreTai Securities Market : 8071) and JBON International Co., Ltd. (stock code in GreTai Securities Market : 1566), the director of Celxpert Energy Corporation (stock code in GreTai Securities Market : 3323), the general manager of Ability I Venture Capital Corporation, Abico Asia Capital Corporation and TranSystem Inc., and the director of HiTi Digital, Inc. and Chien Hwa Coating Technology Inc.

Mr. Hu Xiao Yong - Executive Director

Mr. Hu Xiao Yong was appointed as an Executive Director of the Company in September 2014. He is also an executive director and the chief executive officer of Beijing Enterprises Water Group Limited (HKEX Stock Code: 371), an associate of BPHL, an executive director and the chairman of Beijing Enterprises Clean Energy Group Limited (HKEX Stock Code: 1250) and the vice-chairman of the China Environmental Service Industry Association. Mr. Hu obtained his EMBA degree from the Tsinghua University.

Mr. Hu Yebi - Executive Director

Mr. Hu Yebi was appointed as an executive Director in May 2017. He is the founder and chairman of Vision Finance Group Limited since November 2007. Mr. Hu also holds executive directorships with Hua Lien International (Holding) Company Limited (SEHK Stock Code: 969), BSE and BPHL. Mr. Hu was also appointed as an executive director and chairman of Tai United Holdings Limited (SEHK Stock Code: 718) during the period from July 2014 to January 2016. Mr. Hu received his master’s degree in business administration from the Netherlands International Institute for Management in the Netherlands and postgraduate diploma in management engineering from the Beijing Institute of Technology in Beijing, the PRC. Mr. Hu has more than 24 years of experience in securities and financial services, merger and acquisition and corporate finance.

 

Mr. Qian Xu - Executive Director

Mr. Qian Xu was appointed as an executive Director in May 2017. He is an executive director and the chief executive officer of BPHL since July 2009 and the Chairman of BPHL since June 2016. Mr. Qian was also appointed as a non-executive director of CAQ Holdings Limited (“CAQ”), a company listed on the Australia Stock Exchange with Listing Corporation Code of CAQ in April 2015. Mr. Qian graduated from the Economics and Management Faculty of the Beijing Industrial University with a bachelor’s degree in economics and has obtained his executive master’s degree in business administration from the Tsinghua University. Mr. Qian has extensive experience in mergers and acquisitions, corporate restructuring and financial management.
 

Mr. Siu Kin Wai - Executive Director

Mr. Siu Kin Wai was appointed as an executive Director in May 2017. He is an executive director of BPHL since July 2009 and the president of BPHL since June 2016. He was also appointed as the non-executive director of CAQ in April 2015 and serves as an independent non-executive director of Agritrade Resources Limited (SEHK Stock Code: 1131) since August 2010. Mr. Siu graduated from the City University of Hong Kong with a bachelor’s degree in accountancy and is fellow members of the Association of Chartered Certified Accountants and the Hong Kong Institute of Certified Public Accountants and a member of the Institute of Chartered Accountants in England and Wales. Mr. Siu has extensive experience in financial management and corporate advisory.
 

Mr. Wang Zheng Chun - Executive Director

Mr. Wang Zheng Chun was appointed as an Executive Director of the Company in June 2008. He was the Chairman of the Company during the period from October 2008 to February 2015. He has over ten years of experience in property development and management. Mr. Wang has substantial experience in developing and constructing villas, residential units and commercial buildings in the PRC. Mr. Wang is also the committee member of The Association of Industry and Commerce in Minhang District, Shanghai (上海市閔行區工商業聯合會).

Mr. Robert Winslow Koepp - Independent Non-executive Director

Mr. Robert Winslow Koepp was appointed as a Non-executive Director of the Company in May 2015 and was redesignated as an Independent Non-executive Director in May 2017. Mr. Koepp obtained his bachelor degree in Asian Studies from Pomona College, USA, and Master of Business Administration from Cambridge University in the United Kingdom. Mr. Koepp is proficient in both Chinese and Japanese language and has in-depth professional experience in public and private equity financing, real estate, economics and business strategies, in particular when companies operated in China and listed overseas are involved. He is the author of the following literature: Betting on China: Chinese Stocks, American Stock Markets, and the Wagers on a New Dynamic in Global Capitalism and provides issuers engaging in China healthcare and consuming industry that are listed in The New York Stock Exchange and NASDAQ a series of advices regarding investor relations as well as the best practices for policies of information disclosure.

Mr. Wu Yong Xin - Independent Non-Executive Director

Mr. Wu Yong Xin was appointed as an Independent Non-executive Director of the Company in September 2014. He is currently the Chairman of the Nomination Committee and a member of the Audit Committee and the Remuneration Committee of the Company. Mr. Wu is currently the Senior Vice President, Chief Government Affairs Officer, General Manager of Regional Organization North of Siemens Ltd., China. Mr. Wu obtained his bachelor’s degree in economics in the Capital University of Economics and Trade in Beijing. He started his career in the university as an assistant professor. In 1988, Mr. Wu joined the then Beijing representative office of Siemens as an assistant manager in finance and administration and was seconded to Germany for further management training in headquarters of Siemens in 1992. Since his return to Siemens Ltd., China in 1993, he had participated in business development in the PRC, Korea, Taiwan and the United States of America. In 2007, Mr. Wu was appointed the senior vice president of Siemens Ltd., China and took over the current position since 2010.

Mr. Tse, Man Kit Keith - Independent Non-Executive Director

Mr. Tse Man Kit, Keith was appointed as an Independent Non-executive Director of the Company in September 2014. He is currently the Chairman of the Audit Committee and a member of the Remuneration Committee and the Nomination Committee of the Company. Mr. Tse is also the chief financial officer and company secretary of Shunfeng International Clean Energy Limited (HKEX stock code: 1165) since September 2010 and an independent non-executive director of BSE. Mr. Tse has around 18 years of working experience in accounting and financial management. He worked in a number of international accountant firms from 1997 to 2007, and served as a director of corporate accounting in Flash Electronics, Inc. from January 2007 to January 2008 and a senior qualified accountant in Shanghai Fosun High Technology (Group) Co., Ltd. from February 2008 to August 2010, and the qualified accountant of Fosun International Limited (HKEX stock code: 656) from March 2008 to August 2010. Mr. Tse is a member of Certified Practising Accountant of CPA Australia and a member of the Hong Kong Institute of Certified Public Accountants. Mr. Tse obtained a bachelor’s degree in commerce from University of Wollongong, New South Wales, Australia in July 1997, majoring in accountancy and finance.

Mr. Gary Zhao - Independent Non-Executive Director

Mr. Gary Zhao was appointed as an Independent Non-executive Director of the Company in February 2016. He is currently the Chairman of the Remuneration Committee and a member of the Audit Committee and the Nomination Committee of the Company. Mr. Zhao obtained a bachelor’s degree in English literature from Northeast Normal University and a master’s degree in education from Hebei University in 1984 and 1986, respectively. Mr. Zhao worked in the State Education Commission of the People’s Republic of China since 1986 and was redesignated to work in the Department of Foreign Investment of Beijing Foreign Trade and Economic Relations Commission in 1989. From 1992 to 2005, he served as the general manager of several enterprises, and has subsequently become a full-time freelance investor since 2005. Mr. Zhao has extensive experience in the Chinese economic development, Chinese financial market, project investment and business management.

Mr. Zhang Yun Zhou - Independent Non-executive Director

Mr. Zhang Yun Zhou was appointed as an Independent Non-executive Director of the Company in May 2015. Mr. Zhang has engaged in clinical work of internal medicine and neurology for 24 years. He possesses knowledge in relation to neuroanatomy, neuropathology, electroneurophysiology, neuroimaging and knowledge in relation to other disciplines, and can conduct body check and positioning by the tactical use of the nervous system. He currently focuses on issues of the nervous system and diagnosis and treatment of critical illnesses and conduct integrated management by objectives through the effective combination of neurology, neurosurgery and various specialist disciplines and the integration of fundamental knowledge and clinical practice. He has unique insight towards various aspects including the diagnosis, monitoring and analysis, fluid and electrolyte balance, parenteral and enteral nutrition, prevention of hospital-acquired infection, and tranquilizing, painkilling and sleep in respect of patients suffering from critical neurological illnesses. He is also specialized in treatment and monitoring associated with using ventilator for mechanical ventilation that curbs pathological changes in the nervous system. After finishing his first doctorate degree in Nanfang Hospital of First Military Medical University in Guangzhou and second doctorate degree in Xuanwu Hospital of Capital Medical University in Beijing, Mr. Zhang obtained his qualification of PhD candidate in Clinical Neuropathology from PLA Military Medical School (PLA General Hospital) (解放軍醫進修學院(解放軍總醫院)) in Beijing, a master candidate in Neurology from Zhujiang Hospital of First Military Medical University in Guangzhou and a bachelor degree in Clinical Medicine from The Fourth Military Medical University in Xian, respectively. Mr. Zhang obtained the professional qualification of associate chief physician in Neurology (神經內科副主任醫師) and associate professor in Neurology (神經內科副教授) in 2004 and 2013, respectively. He is currently the medical group leader of Intensive Care Unit of Neurology (神經內科重症病房), and an associate chief physician and associate professor in Xuanwu Hospital of Capital Medical University in Beijing. Mr. Zhang focuses on the scientific research in respect of neuroprotection of ischemic cerebrovascular diseases and infection, mechanical ventilation and fluid and electrolyte balance in respect of patients suffering from critical neurological illnesses.

+ More Board of Directors
Introduction

Beijing Enterprises Medical and Health Industry Group Limited’s highly experienced management team operates in accordance with international industry best practices and strong corporate governance standards. The Group has complied with the code provisions of the Code on Corporate Governance Practices as set out in Appendix 14 of the Listing Rules.

In 2004, after our listing, we established an Audit Committee to assist the Board in its work and to ensure these functions are the subject of rigorous, independent review. In 2006, the Group demonstrated its commitment to corporate governance by establishment of remuneration committee and nomination committee

The following policies are currently adopted by the Group:

 
 
 
 
Audit committee

The Audit Committee was established on 11 April 2002 with written terms of reference, The Board establishes formal and transparent arrangements for considering how it applies the financial reporting and internal control principles and for maintaining an appropriate relationship with the Company’s auditors.

The members of the Audit Committee comprise three independent non-executive directors, Mr. Xie Ming, Mr. Tse Man Kit and Mr. Wu Yong Xin.
 

 
Remuneration committee

The Remuneration Committee was established on 23 May 2006 with written terms of reference. The main objective of the remuneration policy is to ensure that the Group is able to attract, retain and motivate a high-caliber team which is essential to the success of the Group.

The members of the Remuneration Committee comprise three independent non-executive directors, Mr. Xie Ming, Mr. Tse Man Kit and Mr. Wu Yong Xin.
 

 
Nomination committee

The Nomination Committee was established on 20 April 2006 with written terms of reference. It establishes the formal process for identifying and nominating the suitable candidates for the appointment of the Board, reviews the structure, size and composition of the Board and makes recommendations to the Board with regard to any adjustments that are deemed necessary.

The members of the Nomination Committee comprise three independent non-executive directors, Mr. Xie Ming, Mr. Tse Man Kit and Mr. Wu Yong Xin; and one executive director Mr. Zhu Shi Xing.
 

 
Investment And Risk Management Committee

The Investment and Risk Management Committee was established on 8 October 2014, main responsibilities including analyses the economic conditions and to assess the systematic risks and their impact on the Company, develop specific measures for risk management.

The Members of Investment And Risk Management Committee include Mr. Gu Shan Chao, Mr. Zhu Shi Xing, Mr. Liu Xue Heng and Mr. Lam Ka Tak.
 

 
 
 
 

UPCOMING EVENT

S M T W T F S
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31        

WEBSITE

www.bemh.com.hk

COMPANY INFORMATION

Listed Date 26 Apr 2002

Address Unit 8, 21/F,
Greenfield Tower,Concordia Plaza,
No.1 Science Museum Road,
Tsim Sha Tsui East, Kowloon

Telephone (852) 2601 3633

Facsimile (852) 2681 2789

Email enquiry@bemh.com.hk

No. of Click Rate

136540